A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to learn if AMG 673 can help to control acute myeloid leukemia (AML) that is relapsed (has come back) or refractory (has not responded to treatment). Researchers also want to find the highest tolerable dose of AMG 673 that can be given to patients in Part 2 of this study. The safety of the drug will also be studied. This is the first study using AMG 673 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: AMG 673
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Amgen Inc.
IRB Review and Approval Date: 12/29/2017
Recruitment Status: Open
Projected Accrual: 80
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: